GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shire PLC (NAS:SHPG) » Definitions » Tax Expense

Shire (SHPG) Tax Expense : $-2,031 Mil (TTM As of Sep. 2018)


View and export this data going back to 1998. Start your Free Trial

What is Shire Tax Expense?

Shire's tax expense for the months ended in Sep. 2018 was $203 Mil. Its tax expense for the trailing twelve months (TTM) ended in Sep. 2018 was $-2,031 Mil.


Shire Tax Expense Historical Data

The historical data trend for Shire's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shire Tax Expense Chart

Shire Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Tax Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 277.90 56.10 46.10 -126.10 -2,357.60

Shire Quarterly Data
Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.50 -2,402.20 43.30 124.40 203.30

Shire Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Sep. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2,031 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shire  (NAS:SHPG) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Shire Tax Expense Related Terms

Thank you for viewing the detailed overview of Shire's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Shire (SHPG) Business Description

Traded in Other Exchanges
N/A
Address
Shire is a diversified, Ireland-based specialty drug firm. Shire has grown primarily through mergers and acquisitions, including the Transkaryotic Therapies acquisition in 2005, which established its genetic disease business with Replagal and Elaprase, and the merger with New River in 2007, which brought full rights to neuroscience drug Vyvanse. Shire completed the acquisition of ViroPharma (genetic diseases) in 2014, NPS Pharma (internal medicine) in 2015, and Baxalta (hematology, immunology, and oncology) and Dyax (genetic diseases) in 2016.
Executives
James H Cavanaugh director 265 HOTHORPE LANE, VILLANOVA PA 19085